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ERRATUM
Yonago Acta Med. 2020;63(3):188–197 doi: 10.33160/yam.2020.08.009
There was an error in the notation of the number of administrations. The notation should be corrected as follows:
On page 191, left column, line 25
Error: Three patients (17.6%) were given 0.1 mg bid (twice-daily), twelve (70.6%), 0.2 mg bid, and two (11.8%), 0.4 
mg bid of pemafibrate, respectively.
Correction: Three patients (17.6%) were given 0.1 mg qd (once-daily), twelve (70.6%), 0.1 mg bid (twice-daily), and 
two (11.8%), 0.2 mg bid of pemafibrate, respectively
On page 191, right column, line 8
Error: Three biopsy-proven NASH patients were administered 0.2 mg bid of pemafibrate.
Correction: Three biopsy-proven NASH patients were administered 0.2 mg daily of pemafibrate.
On page 191, right column, line 39
Error: Fenofibrate administration needs to be at least 106.6 mg to 160 mg qd (once-daily); on the other hand, only 0.2 
to 0.4 mg bid of pemafibrate is needed.
Correction: Fenofibrate administration needs to be at least 106.6 mg to 160 mg qd; on the other hand, only 0.2 to 0.4 
mg daily of pemafibrate is needed.
On page 192, right column, line 2
Error: In phase 3, 58 (53.2%) subjects with fatty liver were administered 0.2 mg or 0.4 mg bid of pemafibrate;
Correction: In phase 3, 58 (53.2%) subjects with fatty liver were administered 0.2 mg or 0.4 mg daily of pemafibrate;
On page 195, right column, line 6
Error: Both were administered 0.2 mg bid.
Correction: Both were administered 0.2 mg daily.
The authors sincerely apologize for these errors and any confusion they may have caused.
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